Larotrectinib

Drug Profile

Larotrectinib

Alternative Names: ARRY 470; LOXO-101

Latest Information Update: 13 Jul 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Loxo Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Solid tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II CNS cancer
  • Preclinical Acute lymphoblastic leukaemia

Most Recent Events

  • 10 Jul 2017 National Cancer Institute plans a phase II trial for Solid tumours, Non Hodgkin lymphoma, Histiocytosis (In infants, In children, In adolescents, In adults, with NTRK fusions, Second-line therapy or greater) in USA (PO) (NCT03213704)
  • 03 Jun 2017 Efficacy data from a phase I/II trial in Solid tumours released by Solid tumours
  • 03 Jun 2017 Pooled efficacy and adverse data from a phase I trial, phase II NAVIGATE and phase I/II SCOUT trial in Solid tumours released by Lox Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top